18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

Clinical Cancer Research

Volumn 23, Issue 6, 2017, Pages 1432-1441

  Quintela Fandino, Miguel ^a   Lluch, Ana ^b   Manso, Luis ^c   Calvo, Isabel ^d   Cortes, Javier ^e,f   García Saenz, José Angel ^g   Gil Gil, Miguel ^h   Martinez Jánez, Noelia ^f   Gonzalez Martin, Antonio ⁱ   Adrover, Encarna ^j   De Andres, Raquel ^k   Viñas, Gemma ^h   Llombart Cussac, Antonio ^l   Alba, Emilio ^m   Guerra, Juan ⁿ   Bermejo, Begoña ^b   Zamora, Esther ^e   Moreno Anton, Fernando ^g   Simon, Sonia Pernas ^h   Carrato, Alfredo ^f   Lopez Alonso, Antonio ^a   Escudero, María José ^o   Campo, Ruth ^o   Carrasco, Eva ^o   Palacios, José ^f   Mulero, Francisca ^a   Colomer, Ramon ^p   more..

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Hospital de Monteprincipe   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ MD ANDERSON CANCER CENTER   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^l HOSPITAL ARNAU DE VILANOVA   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^o GEICAM   (Spain)

^p HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; NINTEDANIB; PACLITAXEL; PROGESTERONE RECEPTOR; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ERBB2 PROTEIN, HUMAN; INDOLE DERIVATIVE; MISONIDAZOLE; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ACNE; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHOLESTATIC HEPATITIS; CLINICAL EFFECTIVENESS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIARRHEA; DRY SKIN; DYSGEUSIA; EARLY CANCER; EPISTAXIS; FATIGUE; FEMALE; GASTRITIS; GASTROINTESTINAL PAIN; HEADACHE; HEARTBURN; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MIGRAINE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEOADJUVANT THERAPY; NEUTROPENIA; OPEN STUDY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH PERFORATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; AGED; ANALOGS AND DERIVATIVES; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFECTS; GENETICS; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; TUMOR HYPOXIA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; MISONIDAZOLE; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; TUMOR HYPOXIA;

EID: 85016160052     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0738     Document Type: Article

References (41)

1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82.
2. Quintela-Fandino M, Urruticoechea A, Guerra J, Gil M, Gonzalez-Martin A, Marquez R, et al. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). Br J Cancer 2014;111:1060-4.
3. Reck M, Kaiser R,Mellemgaard A, Douillard JY, Orlov S, KrzakowskiM, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-55.
4. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29:3798-804.
5. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31:2205-18.
6. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T. Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis 2014;7:9-18.
7. Becker JC, Andersen MH, Schrama D, Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 2013;62:1137-48.
8. Fuso Nerini I, Morosi L, Zucchetti M, Ballerini A, Giavazzi R, D'Incalci M. Intratumor heterogeneity and its impact on drug distribution and sensitivity. Clin Pharmacol Ther 2014;96:224-38.
9. Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 2014;105:1334-42.
10. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561-6.
11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
12. Hernandez-Agudo E, Mondejar T, Soto-Montenegro ML, Megias D, Mouron S, Sanchez J, et al. Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. Mol Oncol 2016;10:704-18.
13. Jimenez-Valerio G, Martinez-Lozano M, Bassani N, Vidal A, Ochoa-deOlza M, Suarez C, et al. Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients. Cell Rep 2016;15:1134-43.
14. Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J, et al. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep 2016;15:1161-74.
15. Allen E, Mieville P, Warren CM, Saghafinia S, Li L, Peng MW, et al. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep 2016;15:1144-60.
16. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012;72:402-7.
17. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after antiVEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012;21:82-91.
18. Tung JC, Barnes JM, Desai SR, Sistrunk C, Conklin MW, Schedin P, et al. Tumor mechanics and metabolic dysfunction. Free Radic Biol Med 2015;79:269-80.
19. Mitchell RA, Yaddanapudi K. Stromal-dependent tumor promotion by MIF family members. Cell Signal 2014;26:2969-78.
20. Martinez-Outschoorn U, Sotgia F, Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol 2014;41:195-216.
21. Martinez-Outschoorn UE, Lisanti MP. Tumor microenvironment: introduction. Semin Oncol 2014;41:145.
22. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 2004;45:1851-9.
23. Theze B, Bernards N, Beynel A, Bouet S, Kuhnast B, Buvat I, et al. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma. BMC Cancer 2015;15:534.
24. Wiedenmann NE, Bucher S, Hentschel M, Mix M, Vach W, Bittner MI, et al. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. Radiother Oncol 2015;117:113-7.
25. Sato J, Kitagawa Y, Yamazaki Y, Hata H, Asaka T, Miyakoshi M, et al. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2014;41:2031-41.
26. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomographydetected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104.
27. Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X, et al. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med 2013;54:333-40.
28. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-22.
29. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17: 3412-7.
30. Dieras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004;22:4958-65.
31. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, MericBernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533-40.
32. Crown JP, Dieras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013; 31:2870-8.
33. Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, et al. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials 2013;14:228.
34. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011;12:369-76.
35. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptornegative breast cancerdagger. Ann Oncol 2014;25:1122-7.
36. Kutluk Cenik B, Ostapoff KT, Gerber DE, Brekken RA. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther 2013;12:992-1001.
37. Gaustad JV, Simonsen TG, Leinaas MN, Rofstad EK. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC Cancer 2012;12:388.
38. Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, et al. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 2012;41:1593-600.
39. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
40. Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A 2015;112:14325-30.
41. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 2013;110:19059-64.